Key Highlights

  • A $1.15 per-share loss, totaling $111.4 million, marked the third quarter of 2026, while the 2025 comparison period showed $1.17 per share, or $106.4 million in aggregate.
  • Against $0.9 million a year before, Revenue rose to $12.7 million.
  • Cash, equivalents and marketable securities summed to $2,276.6 million on Sep 30, 2026.
  • Net collaboration costs eased to $41.3 million, while a year before they had been $57.1 million, reflecting a larger CASGEVY revenue share.
  • Losses over nine months narrowed to $325.5 million, versus approximately $451.0 million (calculated) earlier.

Deferred Collaboration Revenue Lifts the Top Line While the Quarterly Loss Edges Wider

The filing covering the three months through Sep 30, 2026 was submitted on Nov 2, 2026 by CRISPR Therapeutics (NASDAQ:CRSP). The company's net loss reached $111.4 million, which works out to $1.15 per share, slightly larger in total than the $106.4 million recorded in the same period of 2025.

Revenue rose to $12.7 million from a much smaller base of $0.9 million. Almost all of it, $12.3 million, was deferred collaboration revenue released after the partner opted out of an option on a specific target.

This Swiss company works on gene medicines built around CRISPR/Cas9, spanning hemoglobin disorders, in vivo editing, CAR-T therapy and regenerative medicine. Alongside a partner, it shares development and sales of CASGEVY, a sickle cell and Beta thalassemia treatment that was the first CRISPR-based therapy cleared for use.

Research Spending Up 22%, Partly Offset by Lower Collaboration Costs

R&D outlays grew to $71.9 million, up from $58.9 million, mainly because outside program costs and license fees went up. Acquired in-process R&D added $11.7 million, almost entirely a milestone payment linked to the siRNA pact with Sirius Therapeutics. G&A expense landed at $17.9 million, up from $16.9 million.

Net collaboration costs eased to $41.3 million, compared with $57.1 million in 2025, and management tied the drop to a larger slice of CASGEVY revenue. Operating outlays totaled $142.7 million, compared with $132.9 million before, and the operating shortfall was $130.0 million, slightly narrower than $132.1 million a year earlier.

Other income, net, totaled $18.7 million, versus $26.2 million, reflecting interest on convertible notes and changes in the Fair Value of Equity holdings. Nine-month losses came to $325.5 million, down from roughly $451.0 million (calculated); on a per-share basis, $3.38 versus $5.12.

CTX310 One-Year Phase 1a Results Anchor the Clinical Story

In August 2026, one-year Phase 1a results for CTX310, an in vivo ANGPTL3 program, were presented at a European cardiology congress and printed simultaneously in a major journal. The top-dose cohort averaged reductions of 79% in ANGPTL3, 48% in triglycerides and 53% in LDL cholesterol, with no serious adverse events linked to treatment. Two U.S. RMAT designations apply to the program.

CTX340, aimed at refractory hypertension, and CTX460, aimed at alpha-1 antitrypsin deficiency, sit in Phase 1. CTX611, a long-acting Factor XI siRNA, is in Phase 2, and a knee arthroplasty trial has just completed enrollment.

Liquidity Sufficient for At Least 24 Months Despite $282.1 Million Operating Outflow

Leadership anticipates that present resources can meet requirements for a minimum of two years, not counting partner receipts, against a $2,276.6 million balance of cash and securities as of Sep 30, 2026. Operating Activities consumed $282.1 million across nine months, up from $252.5 million a year before.

Convertible senior notes totaling $600.0 million come due March 1, 2031, with an opening conversion price of about $76.56 per share. The filing has no dated readout; the next signals to watch are clinical updates from the in vivo, cell therapy and siRNA efforts.